title: A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act.
abstract: Patients with chronic HCV have predictable overlapping comorbidities that reduce access to care. The Affordable Care Act (ACA) presents an opportunity to focus on the benefits of the medical home model for integrated chronic disease management. New, highly effective HCV treatment regimens in combination with the medical home model could reduce disease prevalence. We sought to address challenges posed by comorbidities in patients with chronic HCV infection and limitations within our health care system, and recommend solutions to maximize the public benefit from ACA and the new drug regimen.
authors.affiliation: Sean J. Haley is with the Department of Health and Nutrition Sciences, Brooklyn College and the City University of New York, School of Public Health, New York. Mary Jeanne Kreek is with the Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York.
authors.forename: Sean J
authors.initials: SJ
authors.lastname: Haley
authors.forename: Mary Jeanne
authors.initials: MJ
authors.lastname: Kreek
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D015897:Comorbidity; D017277:Drug Approval; D004359:Drug Therapy, Combination; D005838:Genotype; D015658:HIV Infections / Q000453:epidemiology; D006297:Health Services Accessibility / Q000191:economics / Q000331:legislation & jurisprudence* / Q000639:trends; D006509:Hepatitis B / Q000453:epidemiology; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology / Q000235:genetics; D006575:Heterocyclic Compounds, 3-Ring / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D019458:Insurance Coverage / Q000191:economics / Q000331:legislation & jurisprudence*; D001523:Mental Disorders / Q000453:epidemiology; D058991:Patient Protection and Affordable Care Act / Q000191:economics / Q000592:standards*; D011159:Population Surveillance; D011203:Poverty; D015995:Prevalence; D012307:Risk Factors; D000069616:Simeprevir; D000069474:Sofosbuvir; D015819:Substance Abuse, Intravenous / Q000453:epidemiology; D013449:Sulfonamides / Q000191:economics / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology; D014542:Uridine Monophosphate / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D006575:Heterocyclic Compounds, 3-Ring; D013449:Sulfonamides; D000069616:Simeprevir; D014542:Uridine Monophosphate; D000069474:Sofosbuvir